1
|
Díaz-Coránguez M, González-González L, Wang A, Liu X, Antonetti DA. Disheveled-1 Interacts with Claudin-5 and Contributes to Norrin-Induced Endothelial Barrier Restoration. Cells 2023; 12:2402. [PMID: 37830616 PMCID: PMC10571979 DOI: 10.3390/cells12192402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 09/27/2023] [Accepted: 09/29/2023] [Indexed: 10/14/2023] Open
Abstract
Previous studies have revealed that norrin can reverse vascular endothelial-growth-factor (VEGF)-induced permeability in a β-catenin-dependent pathway. Here, we have explored the contribution of disheveled-1 (DVL1) in norrin-induced blood-retinal barrier (BRB) restoration. We provide evidence that in addition to canonical signaling, DVL1 promotes tight junction (TJ) stabilization through a novel, non-canonical signaling pathway involving direct claudin-5 (CLDN5) binding. Immunofluorescence staining of rat retinal cross-sections showed enriched expression of DVL1 and 3 at endothelial capillaries and co-localization with CLDN5 and ZO-1 at the TJ complex in primary bovine retinal endothelial cells (BRECs). Barrier properties of BRECs were determined via measurements of trans-endothelial electrical resistance (TEER) or permeability to 70 kDa RITC-dextran. These studies demonstrated that norrin restoration of barrier properties after VEGF treatment required DVL1 as an siRNA knockdown of Dvl1 but not Dvl2 or Dvl3, reduced basal barrier properties and ablated norrin-induced barrier restoration. However, loss of Dvl1 did not decrease β-catenin signaling activity as measured by Axin2 mRNA expression, suggesting the contribution of a non-canonical pathway. DVL and TJ protein interactions were analyzed via co-immunoprecipitation of endogenous protein in BRECs, which demonstrated that DVL1 interacts with both CLDN5 and ZO-1, while DVL3 interacts only with ZO-1. These interactions were most abundant after inducing BRB restoration by treating BRECs with VEGF and norrin. DVL has previously been shown to form intramolecular bindings between the C-terminal PDZ-binding motif (PDZ-BM) with an internal PDZ domain. Co-transfection of HEK293 cells with DVL1 and CLDN5 or relevant mutants revealed that DVL1 interacts with CLDN5 through the DVL PDZ domain binding, CLDN5 PDZ-BM, in competition with DVL1 PDZ-BM, since DVL/CLDN5 interaction increases with deletion of the DVL1 PDZ-BM and decreases by co-expressing the C-terminal fragment of DVL1 containing the PDZ-BM or through deletion of CLDN5 PDZ-BM. In BREC cells, transfection of the C-terminal fragment of DVL1 downregulates the expression of CLDN5 but does not affect the expression of other proteins of the TJs, including ZO-1, occludin, CLDN1 or VE-cadherin. Blocking DVL1/CLDN5 interaction increased basal permeability and prevented norrin induction of barrier properties after VEGF. Combined with previous data, these results demonstrate that norrin signals through both a canonical β-catenin pathway and a non-canonical signaling pathway by which DVL1 directly binds to CLDN5 to promote barrier properties.
Collapse
Affiliation(s)
- Mónica Díaz-Coránguez
- Department of Pharmacobiology, Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV-IPN), Mexico City 07360, Mexico;
| | - Laura González-González
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI 48105, USA; (L.G.-G.); (A.W.); (X.L.)
| | - Amy Wang
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI 48105, USA; (L.G.-G.); (A.W.); (X.L.)
| | - Xuwen Liu
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI 48105, USA; (L.G.-G.); (A.W.); (X.L.)
| | - David A. Antonetti
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI 48105, USA; (L.G.-G.); (A.W.); (X.L.)
| |
Collapse
|
2
|
Fernández-Tabanera E, García-García L, Rodríguez-Martín C, Cervera ST, González-González L, Robledo C, Josa S, Martínez S, Chapado L, Monzón S, Melero-Fernández de Mera RM, Alonso J. CD44 Modulates Cell Migration and Invasion in Ewing Sarcoma Cells. Int J Mol Sci 2023; 24:11774. [PMID: 37511533 PMCID: PMC10381016 DOI: 10.3390/ijms241411774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 07/18/2023] [Accepted: 07/19/2023] [Indexed: 07/30/2023] Open
Abstract
The chimeric EWSR1::FLI1 transcription factor is the main oncogenic event in Ewing sarcoma. Recently, it has been proposed that EWSR1::FLI1 levels can fluctuate in Ewing sarcoma cells, giving rise to two cell populations. EWSR1::FLI1low cells present a migratory and invasive phenotype, while EWSR1::FLI1high cells are more proliferative. In this work, we described how the CD44 standard isoform (CD44s), a transmembrane protein involved in cell adhesion and migration, is overexpressed in the EWSR1::FLI1low phenotype. The functional characterization of CD44s (proliferation, clonogenicity, migration, and invasion ability) was performed in three doxycycline-inducible Ewing sarcoma cell models (A673, MHH-ES1, and CADO-ES1). As a result, CD44s expression reduced cell proliferation in all the cell lines tested without affecting clonogenicity. Additionally, CD44s increased cell migration in A673 and MHH-ES1, without effects in CADO-ES1. As hyaluronan is the main ligand of CD44s, its effect on migration ability was also assessed, showing that high molecular weight hyaluronic acid (HMW-HA) blocked cell migration while low molecular weight hyaluronic acid (LMW-HA) increased it. Invasion ability was correlated with CD44 expression in A673 and MHH-ES1 cell lines. CD44s, upregulated upon EWSR1::FLI1 knockdown, regulates cell migration and invasion in Ewing sarcoma cells.
Collapse
Affiliation(s)
- Enrique Fernández-Tabanera
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (U758, CB06/07/1009, CIBERER-ISCIII), 28029 Madrid, Spain
- Universidad Nacional de Educación a Distancia (UNED), 28015 Madrid, Spain
| | - Laura García-García
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain
| | - Carlos Rodríguez-Martín
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (U758, CB06/07/1009, CIBERER-ISCIII), 28029 Madrid, Spain
| | - Saint T Cervera
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (U758, CB06/07/1009, CIBERER-ISCIII), 28029 Madrid, Spain
| | - Laura González-González
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain
| | - Cristina Robledo
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain
| | - Santiago Josa
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain
| | - Selene Martínez
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain
| | - Luis Chapado
- Bioinformatics Unit, Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain
| | - Sara Monzón
- Bioinformatics Unit, Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain
| | - Raquel M Melero-Fernández de Mera
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (U758, CB06/07/1009, CIBERER-ISCIII), 28029 Madrid, Spain
| | - Javier Alonso
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (U758, CB06/07/1009, CIBERER-ISCIII), 28029 Madrid, Spain
| |
Collapse
|
3
|
Almansa R, Eiros JM, de Gonzalo-Calvo D, Postigo T, Ortega A, Lopez-Izquierdo R, Moncusí-Moix A, Gort-Paniello C, Dominguez-Gil M, Fuente ADL, González-González L, Luis-García T, García-Mateo N, Tedim AP, Rodríguez-Jara F, Jorge N, González J, Torres G, Gutiérrez-Pérez ON, Villegas MJ, Campo S, Ayllon E, Albi TR, de Frutos Arribas J, Domingo AA, Abadia-Otero J, Barquero JG, Trapiello W, Garcia Frade LJ, Inglada L, Campo FD, Bermejo-Martin JF, Barbé F, Torres A. N-antigenemia detection by a rapid lateral flow test predicts 90-day mortality in COVID-19: a prospective cohort study. Clin Microbiol Infect 2022; 28:1391.e1-1391.e5. [PMID: 35654316 PMCID: PMC9150910 DOI: 10.1016/j.cmi.2022.05.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 05/03/2022] [Accepted: 05/14/2022] [Indexed: 11/28/2022]
Abstract
Objectives To evaluate if the detection of N antigen of SARS-CoV-2 in plasma by a rapid lateral flow test predicts 90-day mortality in COVID-19 patients hospitalized at the wards. Methods The presence of N-antigenemia was evaluated in the first 36 hours after hospitalization in 600 unvaccinated COVID-19 patients, by using the Panbio COVID-19 Ag Rapid Test Device from Abbott (Abbott Laboratories Inc., Chicago, IL, USA). The impact of N-antigenemia on 90-day mortality was assessed by multivariable Cox regression analysis. Results Prevalence of N-antigenemia at hospitalization was higher in nonsurvivors (69% (82/118) vs. 52% (250/482); p < 0.001). The patients with N-antigenemia showed more frequently RNAemia (45.7% (148/324) vs. 19.8% (51/257); p < 0.001), absence of anti-SARS-CoV-2 N antibodies (80.7% (264/327) vs. 26.6% (69/259); p < 0.001) and absence of S1 antibodies (73.4% (240/327) vs. 23.6% (61/259); p < 0.001). The patients with antigenemia showed more frequently acute respiratory distress syndrome (30.1% (100/332) vs. 18.7% (50/268); p = 0.001) and nosocomial infections (13.6% (45/331) vs. 7.9% (21/267); p = 0.026). N-antigenemia was a risk factor for increased 90-day mortality in the multivariable analysis (HR, 1.99 (95% CI,1.09–3.61), whereas the presence of anti-SARS-CoV-2 N-antibodies represented a protective factor (HR, 0.47 (95% CI, 0.26–0.85). Discussion The presence of N-antigenemia or the absence of anti-SARS-CoV-2 N-antibodies after hospitalization is associated to increased 90-day mortality in unvaccinated COVID-19 patients. Detection of N-antigenemia by using lateral flow tests is a quick, widely available tool that could contribute to early identify those COVID-19 patients at risk of deterioration.
Collapse
Affiliation(s)
- Raquel Almansa
- Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain; Department of Cellular Biology, Hystology and Pharmacology. University of Valladolid, Av. Ramón y Cajal, 7, 47005 Valladolid, Spain; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain
| | - Jose María Eiros
- Microbiology Service, Hospital Universitario Rio Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - David de Gonzalo-Calvo
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Av. Alcalde Rovira Roure, 80, 25198 Lleida Spain
| | - Tamara Postigo
- Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain; Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Alicia Ortega
- Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain; Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Raul Lopez-Izquierdo
- Emergency Department, Hospital Universitario Rio Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Anna Moncusí-Moix
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Av. Alcalde Rovira Roure, 80, 25198 Lleida Spain
| | - Clara Gort-Paniello
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Av. Alcalde Rovira Roure, 80, 25198 Lleida Spain
| | - Marta Dominguez-Gil
- Microbiology Service, Hospital Universitario Rio Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Amanda de la Fuente
- Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain; Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Laura González-González
- Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain
| | - Tania Luis-García
- Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain
| | - Nadia García-Mateo
- Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain; Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Ana P Tedim
- Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain; Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Fátima Rodríguez-Jara
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Av. Alcalde Rovira Roure, 80, 25198 Lleida Spain
| | - Noelia Jorge
- Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain
| | - Jessica González
- Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Av. Alcalde Rovira Roure, 80, 25198 Lleida Spain
| | - Gerard Torres
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Av. Alcalde Rovira Roure, 80, 25198 Lleida Spain
| | - Oliver Norberto Gutiérrez-Pérez
- Hematology Service. Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Maria José Villegas
- Hematology Service. Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Sonia Campo
- Hematology Service. Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Eva Ayllon
- Hematology Service. Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Tomás Ruiz Albi
- Pneumology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Julio de Frutos Arribas
- Pneumology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain; Deparment of Medicine, Dermatology and Toxicology, School of Medicine, University of Valladolid, Av. Ramón y Cajal, 7, 47005 Valladolid, Spain
| | - Ainhoa Arroyo Domingo
- Pneumology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Jesica Abadia-Otero
- Internal Medicine Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Julia Gómez Barquero
- Internal Medicine Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Wysali Trapiello
- Clinical Analysis Service. Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud de Castilla y León, Av. Ramón y Cajal, 3, 47003 Valladolid, Spain
| | - Luis Javier Garcia Frade
- Hematology Service. Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Luis Inglada
- Internal Medicine Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain
| | - Felix Del Campo
- Pneumology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain; Deparment of Medicine, Dermatology and Toxicology, School of Medicine, University of Valladolid, Av. Ramón y Cajal, 7, 47005 Valladolid, Spain; Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain
| | - Jesús F Bermejo-Martin
- Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Calle Dulzaina, 2, 47012 Valladolid, Spain.
| | - Ferran Barbé
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Av. Alcalde Rovira Roure, 80, 25198 Lleida Spain
| | - Antoni Torres
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Department of Pulmonology, Hospital Clinic de Barcelona, Universidad de Barcelona, Institut D investigacions August Pi I Sunyer (IDIBAPS), Carrer del Rosselló, 149, 08036 Barcelona, Spain; Catalan Institution for Research and Advanced Studies, Passeig de Lluís Companys, 23, 08010 Barcelona, Spain
| |
Collapse
|
4
|
García-Souto V, Foray S, Lorenzana R, Veiga-López M, Pereira-Crespo S, González-González L, Flores-Calvete G, Báez D, Botana A, Resch-Zafra C. Assessment of greenhouse gas emissions in dairy cows fed with five forage systems. Italian Journal of Animal Science 2022. [DOI: 10.1080/1828051x.2022.2036641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- V. García-Souto
- AGACAL. Agricultural Research Center of Mabegondo (Centro de Investigacións Agrarias de Mabegondo – CIAM), Mabegondo, A Coruña, Spain
| | - S. Foray
- Institute de l’elevage (IDELE), París, France
| | - R. Lorenzana
- Galician Interprofessional Laboratory of Milk Analysis (Laboratorio Interprofesional Galego de Análise do Leite – LIGAL), Mabegondo, A Coruña, Spain
| | - M. Veiga-López
- AGACAL. Agricultural Research Center of Mabegondo (Centro de Investigacións Agrarias de Mabegondo – CIAM), Mabegondo, A Coruña, Spain
| | - S. Pereira-Crespo
- AGACAL. Agricultural Research Center of Mabegondo (Centro de Investigacións Agrarias de Mabegondo – CIAM), Mabegondo, A Coruña, Spain
| | - L. González-González
- AGACAL. Agricultural Research Center of Mabegondo (Centro de Investigacións Agrarias de Mabegondo – CIAM), Mabegondo, A Coruña, Spain
| | - G. Flores-Calvete
- AGACAL. Agricultural Research Center of Mabegondo (Centro de Investigacións Agrarias de Mabegondo – CIAM), Mabegondo, A Coruña, Spain
| | - D. Báez
- AGACAL. Agricultural Research Center of Mabegondo (Centro de Investigacións Agrarias de Mabegondo – CIAM), Mabegondo, A Coruña, Spain
| | - A Botana
- AGACAL. Agricultural Research Center of Mabegondo (Centro de Investigacións Agrarias de Mabegondo – CIAM), Mabegondo, A Coruña, Spain
| | - C. Resch-Zafra
- AGACAL. Agricultural Research Center of Mabegondo (Centro de Investigacións Agrarias de Mabegondo – CIAM), Mabegondo, A Coruña, Spain
| |
Collapse
|
5
|
García-García L, Fernández-Tabanera E, Cervera ST, Melero-Fernández de Mera RM, Josa S, González-González L, Rodríguez-Martín C, Grünewald TGP, Alonso J. The Transcription Factor FEZF1, a Direct Target of EWSR1-FLI1 in Ewing Sarcoma Cells, Regulates the Expression of Neural-Specific Genes. Cancers (Basel) 2021; 13:5668. [PMID: 34830820 PMCID: PMC8616448 DOI: 10.3390/cancers13225668] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Revised: 11/09/2021] [Accepted: 11/10/2021] [Indexed: 11/16/2022] Open
Abstract
Ewing sarcoma is a rare pediatric tumor characterized by chromosomal translocations that give rise to aberrant chimeric transcription factors (e.g., EWSR1-FLI1). EWSR1-FLI1 promotes a specific cellular transcriptional program. Therefore, the study of EWSR1-FLI1 target genes is important to identify critical pathways involved in Ewing sarcoma tumorigenesis. In this work, we focused on the transcription factors regulated by EWSR1-FLI1 in Ewing sarcoma. Transcriptomic analysis of the Ewing sarcoma cell line A673 indicated that one of the genes more strongly upregulated by EWSR1-FLI1 was FEZF1 (FEZ family zinc finger protein 1), a transcriptional repressor involved in neural cell identity. The functional characterization of FEZF1 was performed in three Ewing sarcoma cell lines (A673, SK-N-MC, SK-ES-1) through an shRNA-directed silencing approach. FEZF1 knockdown inhibited clonogenicity and cell proliferation. Finally, the analysis of the FEZF1-dependent expression profile in A673 cells showed several neural genes regulated by FEZF1 and concomitantly regulated by EWSR1-FLI1. In summary, FEZF1 is transcriptionally regulated by EWSR1-FLI1 in Ewing sarcoma cells and is involved in the regulation of neural-specific genes, which could explain the neural-like phenotype observed in several Ewing sarcoma tumors and cell lines.
Collapse
Affiliation(s)
- Laura García-García
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (L.G.-G.); (E.F.-T.); (S.T.C.); (R.M.M.-F.d.M.); (S.J.); (L.G.-G.); (C.R.-M.)
| | - Enrique Fernández-Tabanera
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (L.G.-G.); (E.F.-T.); (S.T.C.); (R.M.M.-F.d.M.); (S.J.); (L.G.-G.); (C.R.-M.)
- Centro de Investigación, Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Saint T. Cervera
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (L.G.-G.); (E.F.-T.); (S.T.C.); (R.M.M.-F.d.M.); (S.J.); (L.G.-G.); (C.R.-M.)
- Centro de Investigación, Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Raquel M. Melero-Fernández de Mera
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (L.G.-G.); (E.F.-T.); (S.T.C.); (R.M.M.-F.d.M.); (S.J.); (L.G.-G.); (C.R.-M.)
- Centro de Investigación, Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Santiago Josa
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (L.G.-G.); (E.F.-T.); (S.T.C.); (R.M.M.-F.d.M.); (S.J.); (L.G.-G.); (C.R.-M.)
| | - Laura González-González
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (L.G.-G.); (E.F.-T.); (S.T.C.); (R.M.M.-F.d.M.); (S.J.); (L.G.-G.); (C.R.-M.)
| | - Carlos Rodríguez-Martín
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (L.G.-G.); (E.F.-T.); (S.T.C.); (R.M.M.-F.d.M.); (S.J.); (L.G.-G.); (C.R.-M.)
- Centro de Investigación, Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Thomas G. P. Grünewald
- Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany;
- Hopp-Children’s Cancer Center (KiTZ), 69120 Heidelberg, Germany
- Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany
| | - Javier Alonso
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (L.G.-G.); (E.F.-T.); (S.T.C.); (R.M.M.-F.d.M.); (S.J.); (L.G.-G.); (C.R.-M.)
- Centro de Investigación, Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, 28029 Madrid, Spain
| |
Collapse
|
6
|
González-González L, Gallego-Gutiérrez H, Martin-Tapia D, Avelino-Cruz JE, Hernández-Guzmán C, Rangel-Guerrero SI, Alvarez-Salas LM, Garay E, Chávez-Munguía B, Gutiérrez-Ruiz MC, Hernández-Melchor D, López-Bayghen E, González-Mariscal L. ZO-2 favors Hippo signaling, and its re-expression in the steatotic liver by AMPK restores junctional sealing. Tissue Barriers 2021; 10:1994351. [PMID: 34689705 DOI: 10.1080/21688370.2021.1994351] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
ZO-2 is a peripheral tight junction (TJ) protein whose silencing in renal epithelia induces cell hypertrophy. Here, we found that in ZO-2 KD MDCK cells, in compensatory renal hypertrophy triggered in rats by a unilateral nephrectomy and in liver steatosis of obese Zucker (OZ) rats, ZO-2 silencing is accompanied by the diminished activity of LATS, a kinase of the Hippo pathway, and the nuclear concentration of YAP, the final effector of this signaling route. ZO-2 appears to function as a scaffold for the Hippo pathway as it associates to LATS1. ZO-2 silencing in hypertrophic tissue is due to a diminished abundance of ZO-2 mRNA, and the Sp1 transcription factor is critical for ZO-2 transcription in renal cells. Treatment of OZ rats with metformin, an activator of AMPK that blocks JNK activity, augments ZO-2 and claudin-1 expression in the liver, reduces the paracellular permeability of hepatocytes, and serum bile acid content. Our results suggest that ZO-2 silencing is a common feature of hypertrophy, and that ZO-2 is a positive regulator of the Hippo pathway that regulates cell size. Moreover, our observations highlight the importance of AMPK, JNK, and ZO-2 as therapeutic targets for blood-bile barrier dysfunction.
Collapse
Affiliation(s)
- Laura González-González
- Department of Physiology, Biophysics, and Neurosciences, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico
| | - Helios Gallego-Gutiérrez
- Department of Physiology, Biophysics, and Neurosciences, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico
| | - Dolores Martin-Tapia
- Department of Physiology, Biophysics, and Neurosciences, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico
| | - José Everardo Avelino-Cruz
- Laboratory of Molecular Cardiology, Institute of Physiology, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - Christian Hernández-Guzmán
- Department of Physiology, Biophysics, and Neurosciences, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico
| | - Sergio Israel Rangel-Guerrero
- Department of Genetics and Molecular Biology, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico
| | - Luis Marat Alvarez-Salas
- Department of Genetics and Molecular Biology, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico
| | - Erika Garay
- Department of Physiology, Biophysics, and Neurosciences, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico
| | - Bibiana Chávez-Munguía
- Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico
| | - María Concepción Gutiérrez-Ruiz
- Department of Health Sciences, Autonomous Metropolitan University- Iztapalapa (UAM-I), Mexico City, Mexico; Laboratory of Experimental Medicine, Unit of Translational Medicine, Institute of Biomedical Research, Unam, National Institute of Cardiology "Ignacio Chávez", Mexico City, Mexico
| | | | - Esther López-Bayghen
- Department of Toxicology, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico
| | - Lorenza González-Mariscal
- Department of Physiology, Biophysics, and Neurosciences, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico
| |
Collapse
|
7
|
Calafat M, González-Muñoza C, Fortuny M, Roig C, Calm A, Mombiela A, Cañete F, Bertoletti F, González-González L, Teller-Martín M, Gordillo J, Mañosa M, Garcia-Planella E, Domènech E. Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease. Aging Clin Exp Res 2021; 33:2355-2359. [PMID: 34164799 PMCID: PMC8221095 DOI: 10.1007/s40520-021-01917-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Accepted: 06/16/2021] [Indexed: 12/17/2022]
Abstract
Background Older age has been reported as a risk factor for severe SARS-CoV-2 disease (COVID-19). The impact of immunosuppressants (IMS) on COVID-19 is still under debate. Aim To describe the incidence and severity of COVID-19 in elderly patients with inflammatory bowel disease (IBD) in relation to the use of IMS. Methods IBD patients over 65 years of age were selected and grouped in terms of IMS use. Confirmed COVID-19, adherence to IST, comorbidities and concomitant non-IBD-related treatments between 1st of March 2020 to 1st of March 2021 were recorded. Results Out of 418 patients included, 89 (21.3%) were on IMS. Thirty-two patients (7.7%) had COVID-19, 7 of whom were on IMS (7.6% not on IMS vs. 7.9% on IMS; P = 0.933) and 7 (22%) patients died. Conclusions Incidence of COVID-19 among elderly IBD patients was similar to that reported in the background population, regardless of the use of IMS.
Collapse
Affiliation(s)
- Margalida Calafat
- Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
| | | | - Marta Fortuny
- Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
| | - Cristina Roig
- Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Anna Calm
- Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
| | - Antonio Mombiela
- Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Fiorella Cañete
- Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
| | - Federico Bertoletti
- Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Laura González-González
- Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
| | - Marta Teller-Martín
- Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Jordi Gordillo
- Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Míriam Mañosa
- Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
| | | | - Eugeni Domènech
- Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
- Gastroenterology and Hepatology Department, Hospital Universitari Germans Trias I Pujol, Carretera del Canyet s/n, 08916, Badalona, Catalonia, Spain.
| |
Collapse
|
8
|
Cervera ST, Rodríguez-Martín C, Fernández-Tabanera E, Melero-Fernández de Mera RM, Morin M, Fernández-Peñalver S, Iranzo-Martínez M, Amhih-Cardenas J, García-García L, González-González L, Moreno-Pelayo MA, Alonso J. Therapeutic Potential of EWSR1-FLI1 Inactivation by CRISPR/Cas9 in Ewing Sarcoma. Cancers (Basel) 2021; 13:cancers13153783. [PMID: 34359682 PMCID: PMC8345183 DOI: 10.3390/cancers13153783] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 07/13/2021] [Accepted: 07/23/2021] [Indexed: 01/14/2023] Open
Abstract
Simple Summary Ewing sarcoma is an aggressive tumor with still unacceptable survival rates, particularly in patients with metastatic disease and for which it is necessary to develop new and innovative therapies. These tumors are characterized by the presence of chromosomal translocations that give rise to chimeric transcription factors (i.e., EWSR1–FLI1) that govern the oncogenic process. In this article, we describe an efficient strategy to permanently inactivate the EWSR1–FLI1 oncogene characteristic of Ewing sarcoma using CRISPR/Cas9 gene editing technology. Although the application of gene therapy in cancer still has many limitations, for example, the strategy for delivery, studies like ours show that gene therapy can be a promising alternative, particularly for those tumors that are highly dependent on a particular oncogene as is the case in Ewing sarcoma. Abstract Ewing sarcoma is an aggressive bone cancer affecting children and young adults. The main molecular hallmark of Ewing sarcoma are chromosomal translocations that produce chimeric oncogenic transcription factors, the most frequent of which is the aberrant transcription factor EWSR1–FLI1. Because this is the principal oncogenic driver of Ewing sarcoma, its inactivation should be the best therapeutic strategy to block tumor growth. In this study, we genetically inactivated EWSR1–FLI1 using CRISPR-Cas9 technology in order to cause permanent gene inactivation. We found that gene editing at the exon 9 of FLI1 was able to block cell proliferation drastically and induce senescence massively in the well-studied Ewing sarcoma cell line A673. In comparison with an extensively used cellular model of EWSR1–FLI1 knockdown (A673/TR/shEF), genetic inactivation was more effective, particularly in its capability to block cell proliferation. In summary, genetic inactivation of EWSR1–FLI1 in A673 Ewing sarcoma cells blocks cell proliferation and induces a senescence phenotype that could be exploited therapeutically. Although efficient and specific in vivo CRISPR-Cas9 editing still presents many challenges today, our data suggest that complete inactivation of EWSR1–FLI1 at the cell level should be considered a therapeutic approach to develop in the future.
Collapse
Affiliation(s)
- Saint T. Cervera
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (S.T.C.); (C.R.-M.); (E.F.-T.); (R.M.M.-F.d.M.); (M.I.-M.); (J.A.-C.); (L.G.-G.); (L.G.-G.)
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (CB06/07/1009; CIBERER-ISCIII), 28029 Madrid, Spain
| | - Carlos Rodríguez-Martín
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (S.T.C.); (C.R.-M.); (E.F.-T.); (R.M.M.-F.d.M.); (M.I.-M.); (J.A.-C.); (L.G.-G.); (L.G.-G.)
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (CB06/07/1009; CIBERER-ISCIII), 28029 Madrid, Spain
| | - Enrique Fernández-Tabanera
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (S.T.C.); (C.R.-M.); (E.F.-T.); (R.M.M.-F.d.M.); (M.I.-M.); (J.A.-C.); (L.G.-G.); (L.G.-G.)
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (CB06/07/1009; CIBERER-ISCIII), 28029 Madrid, Spain
| | - Raquel M. Melero-Fernández de Mera
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (S.T.C.); (C.R.-M.); (E.F.-T.); (R.M.M.-F.d.M.); (M.I.-M.); (J.A.-C.); (L.G.-G.); (L.G.-G.)
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (CB06/07/1009; CIBERER-ISCIII), 28029 Madrid, Spain
| | - Matias Morin
- Servicio de Genética, Hospital Universitario Ramón y Cajal, IRYCIS, Carretera de Colmenar km 9.100, 28034 Madrid, Spain; (M.M.); (S.F.-P.); (M.A.M.-P.)
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (CB06/07/0048; CIBERER-ISCIII), 28029 Madrid, Spain
| | - Sergio Fernández-Peñalver
- Servicio de Genética, Hospital Universitario Ramón y Cajal, IRYCIS, Carretera de Colmenar km 9.100, 28034 Madrid, Spain; (M.M.); (S.F.-P.); (M.A.M.-P.)
| | - Maria Iranzo-Martínez
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (S.T.C.); (C.R.-M.); (E.F.-T.); (R.M.M.-F.d.M.); (M.I.-M.); (J.A.-C.); (L.G.-G.); (L.G.-G.)
| | - Jorge Amhih-Cardenas
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (S.T.C.); (C.R.-M.); (E.F.-T.); (R.M.M.-F.d.M.); (M.I.-M.); (J.A.-C.); (L.G.-G.); (L.G.-G.)
| | - Laura García-García
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (S.T.C.); (C.R.-M.); (E.F.-T.); (R.M.M.-F.d.M.); (M.I.-M.); (J.A.-C.); (L.G.-G.); (L.G.-G.)
| | - Laura González-González
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (S.T.C.); (C.R.-M.); (E.F.-T.); (R.M.M.-F.d.M.); (M.I.-M.); (J.A.-C.); (L.G.-G.); (L.G.-G.)
| | - Miguel Angel Moreno-Pelayo
- Servicio de Genética, Hospital Universitario Ramón y Cajal, IRYCIS, Carretera de Colmenar km 9.100, 28034 Madrid, Spain; (M.M.); (S.F.-P.); (M.A.M.-P.)
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (CB06/07/0048; CIBERER-ISCIII), 28029 Madrid, Spain
| | - Javier Alonso
- Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; (S.T.C.); (C.R.-M.); (E.F.-T.); (R.M.M.-F.d.M.); (M.I.-M.); (J.A.-C.); (L.G.-G.); (L.G.-G.)
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (CB06/07/1009; CIBERER-ISCIII), 28029 Madrid, Spain
- Correspondence:
| |
Collapse
|
9
|
Tovar R, Vargas A, Aranda J, Sánchez-Salido L, González-González L, Chowen JA, Rodríguez de Fonseca F, Suárez J, Rivera P. Analysis of Both Lipid Metabolism and Endocannabinoid Signaling Reveals a New Role for Hypothalamic Astrocytes in Maternal Caloric Restriction-Induced Perinatal Programming. Int J Mol Sci 2021; 22:ijms22126292. [PMID: 34208173 PMCID: PMC8230792 DOI: 10.3390/ijms22126292] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2021] [Revised: 06/07/2021] [Accepted: 06/08/2021] [Indexed: 12/29/2022] Open
Abstract
Maternal malnutrition in critical periods of development increases the risk of developing short- and long-term diseases in the offspring. The alterations induced by this nutritional programming in the hypothalamus of the offspring are of special relevance due to its role in energy homeostasis, especially in the endocannabinoid system (ECS), which is involved in metabolic functions. Since astrocytes are essential for neuronal energy efficiency and are implicated in brain endocannabinoid signaling, here we have used a rat model to investigate whether a moderate caloric restriction (R) spanning from two weeks prior to the start of gestation to its end induced changes in offspring hypothalamic (a) ECS, (b) lipid metabolism (LM) and/or (c) hypothalamic astrocytes. Monitorization was performed by analyzing both the gene and protein expression of proteins involved in LM and ECS signaling. Offspring born from caloric-restricted mothers presented hypothalamic alterations in both the main enzymes involved in LM and endocannabinoids synthesis/degradation. Furthermore, most of these changes were similar to those observed in hypothalamic offspring astrocytes in culture. In conclusion, a maternal low caloric intake altered LM and ECS in both the hypothalamus and its astrocytes, pointing to these glial cells as responsible for a large part of the alterations seen in the total hypothalamus and suggesting a high degree of involvement of astrocytes in nutritional programming.
Collapse
Affiliation(s)
- Rubén Tovar
- Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain; (R.T.); (A.V.); (J.A.); (L.S.-S.); (L.G.-G.); (F.R.d.F.)
- UGC Salud Mental, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain
- Andalucia Tech, Facultad de Medicina, Universidad de Málaga, Campus de Teatinos s/n, 29071 Málaga, Spain
| | - Antonio Vargas
- Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain; (R.T.); (A.V.); (J.A.); (L.S.-S.); (L.G.-G.); (F.R.d.F.)
- UGC Salud Mental, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain
| | - Jesús Aranda
- Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain; (R.T.); (A.V.); (J.A.); (L.S.-S.); (L.G.-G.); (F.R.d.F.)
- Andalucia Tech, Facultad de Medicina, Universidad de Málaga, Campus de Teatinos s/n, 29071 Málaga, Spain
| | - Lourdes Sánchez-Salido
- Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain; (R.T.); (A.V.); (J.A.); (L.S.-S.); (L.G.-G.); (F.R.d.F.)
- UGC Salud Mental, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain
| | - Laura González-González
- Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain; (R.T.); (A.V.); (J.A.); (L.S.-S.); (L.G.-G.); (F.R.d.F.)
| | - Julie A. Chowen
- Department of Endocrinology, Instituto de Investigación Biomédica la Princesa, Fundación Investigación Biomédica del Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain;
- CIBEROBN (Centro de Investigación Biomédica en Red Sobre Fisiopatología de la Obesidad y Nutrición), Instituto de Salud Carlos III, 28009 Madrid, Spain
- IMDEA Food Institute, CEI UAM + CSIC, 28009 Madrid, Spain
| | - Fernando Rodríguez de Fonseca
- Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain; (R.T.); (A.V.); (J.A.); (L.S.-S.); (L.G.-G.); (F.R.d.F.)
- UGC Salud Mental, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain
| | - Juan Suárez
- Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain; (R.T.); (A.V.); (J.A.); (L.S.-S.); (L.G.-G.); (F.R.d.F.)
- Departamento de Anatomía Humana, Medicina Legal e Historia de la Ciencia, Universidad de Málaga, 29071 Málaga, Spain
- Correspondence: (J.S.); (P.R.); Tel.: +34-952614012 (J.S.); +34-952614012 (P.R.)
| | - Patricia Rivera
- Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain; (R.T.); (A.V.); (J.A.); (L.S.-S.); (L.G.-G.); (F.R.d.F.)
- UGC Salud Mental, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain
- Correspondence: (J.S.); (P.R.); Tel.: +34-952614012 (J.S.); +34-952614012 (P.R.)
| |
Collapse
|
10
|
Gallego-Gutiérrez H, González-González L, Ramírez-Martínez L, López-Bayghen E, González-Mariscal L. Tight junction protein ZO-2 modulates the nuclear accumulation of transcription factor TEAD. Mol Biol Cell 2021; 32:1347-1358. [PMID: 34010016 PMCID: PMC8694039 DOI: 10.1091/mbc.e20-07-0470] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
The presence of tight junction protein zonula occludens 2 (ZO-2) at the nucleus inhibits the transcription of genes regulated by TEAD transcription factor. Here, we analyzed whether the movement of ZO-2 into the nucleus modulates the nuclear concentration of TEAD. In sparse cultures of ZO-2 knockdown Madin–Darby canine kidney cells, nuclear TEAD was diminished, as in parental cells transfected with a ZO-2 construct without nuclear localization signals, indicating that ZO-2 facilitates the entry of TEAD into the nucleus. Inhibition of nPKCδ in parental cells triggers the interaction between ZO-2 and TEAD at the cytoplasm and facilitates TEAD/ZO-2 complex nuclear importation. Using proximity ligation, immunoprecipitation, and pull-down assays, TEAD/ZO-2 interaction was confirmed. Nuclear TEAD is phosphorylated, and its exit in parental cells is enhanced by activation of a ZO-2 nuclear exportation signal by nPKCε, while the nuclear accumulation of ZO-2 triggered by the mutation of ZO-2 nuclear export signals induces no change in TEAD nuclear concentration. In summary, our results indicate that the movements of ZO-2 in and out of the nucleus modulate the intracellular traffic of TEAD through a process regulated by nPKCδ and ε and provide a novel role of ZO-2 as a nuclear translocator of TEAD.
Collapse
Affiliation(s)
| | | | - Leticia Ramírez-Martínez
- Department of Toxicology, Center for Research and Advanced Studies (Cinvestav), Mexico City 07360, Mexico
| | - Esther López-Bayghen
- Department of Toxicology, Center for Research and Advanced Studies (Cinvestav), Mexico City 07360, Mexico
| | | |
Collapse
|
11
|
Iborra I, Puig M, Marín L, Calafat M, Cañete F, Quiñones C, González-González L, Cardona G, Mañosa M, Domènech E. Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease on Biological Agents During the SARS-CoV-2 Pandemic. Dig Dis Sci 2021; 66:4191-4196. [PMID: 33469807 PMCID: PMC7814978 DOI: 10.1007/s10620-020-06807-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Accepted: 12/22/2020] [Indexed: 12/28/2022]
Abstract
BACKGROUND The outbreak of COVID19 evolved rapidly into a global pandemic, forcing hospitals, including inflammatory bowel disease (IBD) referral units, to change their practices to ensure quality of care. AIMS To describe the clinical outcomes and the fulfilment of the treatment schedule of patients with IBD treated with biological agents in a single-center of a red-zone of the pandemic, and to report the patients' perceptions about COVID-19 and the measures adopted at our center. METHODS Therapeutic adherence and clinical outcomes were collected for all patients undergoing treatment with intravenous biologicals and subcutaneous biologicals at our center. A telephone survey was also performed to assess these patients' perceptions of the COVID pandemic and the related measures adopted at their IBD unit. RESULTS A total of 234 patients were included (117 on intravenous and 117 on subcutaneous biologicals). Only 10% of patients postponed intravenous infusions intentionally and 5% postponed the collection of subcutaneous biologicals at the hospital pharmacy. Only five confirmed COVID-19 cases were registered (2.1%), all of them of mild severity. One hundred and fifty-five patients participated in the survey (77 on intravenous and 78 on subcutaneous drugs). Fear of going to the hospital was the most common reason for postponing biological administrations. Among those on combination therapy, only 7% admitted to have withdrawn immunosuppressants. CONCLUSIONS Adherence to intravenous and subcutaneous biological therapies during the pandemic was high in a single-center cohort of IBD patients even though the cumulative incidence of confirmed COVID-19 was low.
Collapse
Affiliation(s)
- Ignacio Iborra
- grid.411438.b0000 0004 1767 6330Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, 08916 Badalona, Catalonia Spain
| | - Maria Puig
- grid.411438.b0000 0004 1767 6330Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, 08916 Badalona, Catalonia Spain
| | - Laura Marín
- grid.411438.b0000 0004 1767 6330Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, 08916 Badalona, Catalonia Spain
| | - Margalida Calafat
- grid.411438.b0000 0004 1767 6330Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, 08916 Badalona, Catalonia Spain ,grid.452371.60000 0004 5930 4607Centro de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Catalonia, Spain
| | - Fiorella Cañete
- grid.411438.b0000 0004 1767 6330Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, 08916 Badalona, Catalonia Spain ,grid.452371.60000 0004 5930 4607Centro de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Catalonia, Spain
| | - Carles Quiñones
- grid.411438.b0000 0004 1767 6330Pharmacy Department, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia Spain
| | - Laura González-González
- grid.411438.b0000 0004 1767 6330Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, 08916 Badalona, Catalonia Spain
| | - Glòria Cardona
- grid.411438.b0000 0004 1767 6330Pharmacy Department, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia Spain
| | - Míriam Mañosa
- grid.411438.b0000 0004 1767 6330Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, 08916 Badalona, Catalonia Spain ,grid.452371.60000 0004 5930 4607Centro de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Catalonia, Spain
| | - Eugeni Domènech
- grid.411438.b0000 0004 1767 6330Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, 08916 Badalona, Catalonia Spain ,grid.452371.60000 0004 5930 4607Centro de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Catalonia, Spain ,grid.7080.f0000 0001 2296 0625Departament de Medicina, Universitat Autònoma de Barcelona, Catalonia, Spain
| |
Collapse
|
12
|
Sainz-Ramírez A, Botana A, Pereira-Crespo S, González-González L, Veiga M, Resch C, Valladares J, Arriaga-Jordán CM, Flores-Calvete G. Efecto de la fecha de corte y del uso de aditivos en la composición química y calidad fermentativa de ensilado de girasol. REV MEX CIENC PECU 2020. [DOI: 10.22319/rmcp.v11i3.5092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
El objetivo fue evaluar fechas de corte y del uso de aditivos sobre la calidad del ensilado de la planta entera de girasol. La variedad forrajera (Rumbosol-91) se cosechó en las semanas 1, 3 y 5 post-floración (F1, F2 y F3, respectivamente) y tratada con los siguientes aditivos: 1) 1.5 × 105 ufc de inoculante g-1 de forraje, a base de bacterias lácticas homofermentativas Enterococcus faecium, Pediococcus pentosaceus y Lactobacillus plantarum (INOC), 2) 3 ml kg-1 de forraje de una solución al 85% de ácido fórmico (FORM) y 3) sin aditivo (Testigo); siguiendo un diseño factorial 3x3 con cinco repeticiones. La producción de efluente y las pérdidas totales de materia seca (MS) se redujeron, desde 282 y 134 g kg-1 en F+1 hasta 96 y 87 g kg-1 en F+5 como resultado del alto contenido de humedad del forraje próxima a la floración. El análisis NIRS de las muestras de ensilaje mostró que los contenidos de proteína, fibra y digestibilidad descendían significativamente con la madurez de la planta; la rápida acumulación de aceite en la MS hizo que la concentración energética fuese superior en el estado fenológico más avanzado. La calidad fermentativa de los ensilajes fue satisfactoria, independientemente del momento de corte y del uso de aditivo. Se concluye que es preferible el corte de la planta a las cinco semanas post-floración, donde se espera una fermentación aceptable sin necesidad de conservantes.
Collapse
|
13
|
González-González L, González-Ramírez R, Flores A, Avelino-Cruz JE, Felix R, Monjaraz E. Epidermal Growth Factor Potentiates Migration of MDA-MB 231 Breast Cancer Cells by Increasing NaV1.5 Channel Expression. Oncology 2019; 97:373-382. [PMID: 31430760 DOI: 10.1159/000501802] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Accepted: 06/27/2019] [Indexed: 12/24/2022]
Abstract
INTRODUCTION Breast cancer is one of the leading causes of death worldwide and is the result of dysregulation of various signaling pathways in mammary epithelial cells. The mortality rate in patients suffering from breast cancer is high because the tumor cells have a prominent invasive capacity towards the surrounding tissues. Previous studies carried out in tumor cell models show that voltage-gated ion channels may be important molecular actors that contribute to the migratory and invasive capacity of the tumor cells. METHODS In this study, by using an experimental strategy that combines cell and molecular biology assays with electrophysiological recording, we sought to determine whether the voltage-dependent sodium channel NaV1.5 regulates the migratory capacity of the human breast cancer cell line MDA-MB 231, when cells are maintained in the presence of epidermal growth factor (EGF), as an inductor of the epithelial-mesenchymal transition. RESULTS Our data show that EGF stimulates the migratory capacity of MDA-MB 231 cells, by regulating the functional expression of NaV1.5 channels. Consistent with this, the stimulatory actions of the growth factor were prevented by the use of tetrodotoxin, an Na+ channel selective blocker, as well as by resveratrol, an antioxidant that can also affect Na+ channel activity. DISCUSSION The understanding of molecular mechanisms, such as the EGF pathway in the progression of breast cancer is fundamental for the design of more effective therapeutic strategies for the disease.
Collapse
Affiliation(s)
| | - Ricardo González-Ramírez
- Department of Molecular Biology and Histocompatibility, Dr. Manuel Gea González General Hospital, Mexico City, Mexico
| | - Amira Flores
- Institute of Physiology, Meritorious Autonomous University of Puebla (BUAP), Puebla, Mexico
| | - José E Avelino-Cruz
- Institute of Physiology, Meritorious Autonomous University of Puebla (BUAP), Puebla, Mexico
| | - Ricardo Felix
- Department of Cell Biology, Center for Research and Advanced Studies of the National Polytechnic Institute (Cinvestav-IPN), Mexico City, Mexico,
| | - Eduardo Monjaraz
- Institute of Physiology, Meritorious Autonomous University of Puebla (BUAP), Puebla, Mexico
| |
Collapse
|
14
|
González-González L, Alonso J. Periostin: A Matricellular Protein With Multiple Functions in Cancer Development and Progression. Front Oncol 2018; 8:225. [PMID: 29946533 PMCID: PMC6005831 DOI: 10.3389/fonc.2018.00225] [Citation(s) in RCA: 169] [Impact Index Per Article: 28.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Accepted: 05/30/2018] [Indexed: 01/19/2023] Open
Abstract
Tumor microenvironment is considered nowadays as one of the main players in cancer development and progression. Tumor microenvironment is highly complex and consists of non-tumor cells (i.e., cancer-associated fibroblast, endothelial cells, or infiltrating leukocytes) and a large list of extracellular matrix proteins and soluble factors. The way that microenvironment components interact among them and with the tumor cells is very complex and only partially understood. However, it is now clear that these interactions govern and modulate many of the cancer hallmarks such as cell proliferation, the resistance to death, the differentiation state of tumor cells, their ability to migrate and metastasize, and the immune response against tumor cells. One of the microenvironment components that have emerged in the last years with strength is a heterogeneous group of multifaceted proteins grouped under the name of matricellular proteins. Matricellular proteins are a family of non-structural matrix proteins that regulate a variety of biological processes in normal and pathological situations. Many components of this family such as periostin (POSTN), osteopontin (SPP1), or the CNN family of proteins have been shown to regulate key aspect of tumor biology, including proliferation, invasion, matrix remodeling, and dissemination to pre-metastatic niches in distant organs. Matricellular proteins can be produced by tumor cells themselves or by tumor-associated cells, and their synthesis can be affected by intrinsic and/or extrinsic tumor cell factors. In this review, we will focus on the role of POSTN in the development and progression of cancer. We will describe their functions in normal tissues and the mechanisms involved in their regulation. We will analyze the tumors in which their expression is altered and their usefulness as a biomarker of tumor progression. Finally, we will speculate about future directions for research and therapeutic approaches targeting POSTN.
Collapse
Affiliation(s)
- Laura González-González
- Unidad de Tumores Sólidos Infantiles, Área de Genética Humana, Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain
| | - Javier Alonso
- Unidad de Tumores Sólidos Infantiles, Área de Genética Humana, Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
15
|
Quintero-Troconis E, Buelvas N, Carrasco-López C, Domingo-Sananes M, González-González L, Ramírez-Molina R, Osorio L, Lobo-Rojas A, Cáceres A, Michels P, Acosta H, Quiñones W, Concepción J. Enolase from Trypanosoma cruzi is inhibited by its interaction with metallocarboxypeptidase-1 and a putative acireductone dioxygenase. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2018. [DOI: 10.1016/j.bbapap.2018.03.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
16
|
González-Mariscal L, Raya-Sandino A, González-González L, Hernández-Guzmán C. Relationship between G proteins coupled receptors and tight junctions. Tissue Barriers 2018; 6:e1414015. [PMID: 29420165 DOI: 10.1080/21688370.2017.1414015] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Tight junctions (TJs) are sites of cell-cell adhesion, constituted by a cytoplasmic plaque of molecules linked to integral proteins that form a network of strands around epithelial and endothelial cells at the uppermost portion of the lateral membrane. TJs maintain plasma membrane polarity and form channels and barriers that regulate the transit of ions and molecules through the paracellular pathway. This structure that regulates traffic between the external milieu and the organism is affected in numerous pathological conditions and constitutes an important target for therapeutic intervention. Here, we describe how a wide array of G protein-coupled receptors that are activated by diverse stimuli including light, ions, hormones, peptides, lipids, nucleotides and proteases, signal through heterotrimeric G proteins, arrestins and kinases to regulate TJs present in the blood-brain barrier, the blood-retinal barrier, renal tubular cells, keratinocytes, lung and colon, and the slit diaphragm of the glomerulus.
Collapse
Affiliation(s)
- Lorenza González-Mariscal
- a Department of Physiology , Biophysics and Neuroscience, Center for Research and Advanced Studies (Cinvestav) , Mexico City , Mexico
| | - Arturo Raya-Sandino
- a Department of Physiology , Biophysics and Neuroscience, Center for Research and Advanced Studies (Cinvestav) , Mexico City , Mexico
| | - Laura González-González
- a Department of Physiology , Biophysics and Neuroscience, Center for Research and Advanced Studies (Cinvestav) , Mexico City , Mexico
| | - Christian Hernández-Guzmán
- a Department of Physiology , Biophysics and Neuroscience, Center for Research and Advanced Studies (Cinvestav) , Mexico City , Mexico
| |
Collapse
|
17
|
Álvarez-Otero J, Lamas-Ferreiro JL, González-González L, Rodríguez-Conde I, Fernández-Soneira MJ, Arca-Blanco A, Bermúdez-Sanjurjo JR, de la Fuente-Aguado J. [Carbapenem resistance in Pseudomonas aeruginosa isolated from urine cultures: prevalence and risk factors]. Rev Esp Quimioter 2017; 30:183-194. [PMID: 28440605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE Pseudomonas aeruginosa is a non-fermentative gram-negative bacillus with a great ability to develop resistance to multiple antibiotics, including carbapenems, which is a growing problem worldwide. The aim of this study was to analyse the prevalence of carbapenem-resistant P. aeruginosa (CRPA) in urine cultures and to determine the risk factors associated with the development of carbapanem resistance. METHODS Positive urine cultures to P. aeruginosa between September 2012 and September 2014 were identified. We excluded repetitive cultures from the same patient. We created a database with different variables, including antimicrobial resistance. The prevalence of carbapenem resistance and the risk factors for growth of CRPA were analysed. RESULTS Ninety-one patients with positive urine cultures to P. aeruginosa were included. The prevalence of CRPA was 22%. The risk factors to CRPA infection in the univariate analysis were: congestive heart failure (p=0.02), previous treatment with ampicillin (p=0.04), meropenem (p=0.04), piperacillin-tazobactam (p=0.01), trimethoprim-sulfamethoxazole (p= 0.01) and previous treatment with more than one antibiotic (p<0.01). Only congestive heart failure (p<0.01) and previous treatment with more than one antibiotic (p<0.01) showed statistically significant differences in the multivariate analysis. CONCLUSIONS The prevalence of CRPA in urine cultures is high in our population. We should assess the presence of risk factors as previous treatment with more than one antibiotic or comorbidities such as heart failure, in order to select an appropriate empirical treatment in patients with severe urinary tract infections.
Collapse
Affiliation(s)
- J Álvarez-Otero
- Judith Álvarez Otero, Servicio de Medicina Interna, Hospital Povisa, Vigo, España. Hospital Povisa. C/Salamanca, Nº5. CP: 36211, Vigo (Pontevedra) Spain.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Álvarez-Otero J, de la Fuente-Aguado J, Arias-Castaño J, González-González L, Puerta-Louro R, Araújo-Fernández S. Dabigatrán: experiencia en la práctica clínica habitual. Rev Clin Esp 2015; 215:385-90. [DOI: 10.1016/j.rce.2015.05.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Revised: 05/05/2015] [Accepted: 05/15/2015] [Indexed: 10/23/2022]
|
19
|
González-González L, Pérez-Cortéz JG, Flores-Aldana M, Macías-Morales N, Hernández-Girón C. [Antioxidant use as dietary therapy in patients with multiple sclerosis]. Medwave 2015; 15:e6065. [PMID: 25629306 DOI: 10.5867/medwave.2015.01.6065] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2014] [Accepted: 12/22/2014] [Indexed: 11/27/2022] Open
Abstract
INTRODUCTION Multiple sclerosis is an immune-mediated disease that produces chronic inflammation and neural degeneration. The disease progresses with acute attacks that result in myelin inflammation. This in turn increases oxidative stress and favors the appearance of reactive oxygen species. Reactive oxygen species damage neural cells causing apoptosis. The etiology of multiple sclerosis remains unknown and current therapy is aggressive and expensive. Recently, complementary and alternative medicine therapies have been proposed to control pathogenesis and symptoms of this disease. It is believed that these therapies help slow the progression of multiple sclerosis and improve survival. METHODS We conducted a MEDLINE/PubMed search using the following MeSH terms: diet, multiple sclerosis, antioxidants. We selected the main articles containing multiple sclerosis and diet. RESULTS We analyzed three case control studies that evaluated different dietary approaches in multiple sclerosis. For this review, we also included five experimental studies that studied the efficacy of lipoic acid in humans and rodents in diseases like multiple sclerosis, experimental autoimmune encephalomyelitis, and breast cancer.
Collapse
Affiliation(s)
- Laura González-González
- Escuela de Nutrición, Universidad Latinoamericana, Cuernavaca, México. Address: Av. Universidad N°. 655, CP 62100, Cuernavaca, Morelos, México.
| | | | - Mario Flores-Aldana
- Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México
| | - Nayeli Macías-Morales
- Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México
| | - Carlos Hernández-Girón
- Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México
| |
Collapse
|
20
|
Pérez-Carro G, Fau R, González-González L. [Fingerprint microcystic dystrophy: Episodes of irregular astigmatism and their topographical representation]. ACTA ACUST UNITED AC 2011; 86:415-8. [PMID: 22117742 DOI: 10.1016/j.oftal.2011.06.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2010] [Revised: 05/03/2011] [Accepted: 06/03/2011] [Indexed: 12/01/2022]
Abstract
CASE STUDY A 44 year-old male patient suffering from painless bouts of blurred vision and with no visible ophthalmological repercussions initially. After one of these clinical episodes we managed to visualise fingerprint images in the anterior pole, as well as corneal, pachymetric and topographical changes, which in turn produce the symptomatic refractive changes. DISCUSSION Fingerprint keratopathy is a condition diagnosed through recurring corneal erosion. The pathogenic origin of the condition-an altered epithelial basal membrane- may encourage the separation of the corneal epithelium from its underlying layers. Depending on whether this separation is partial or total, this will lead to spontaneous corneal erosion or, less frequently, episodes of blurred vision caused by oedema and corneal swelling.
Collapse
Affiliation(s)
- G Pérez-Carro
- Oftalmología, Hospital de la Cruz Roja, Gijón, Asturias, España.
| | | | | |
Collapse
|
21
|
López-Revuelta K, Fernández-Juárez G, Barba Martín R, Tomás Pin A, González-González L, Portolés Pérez JM. [Current status of the electronic clinical record in outpatient nephrology]. Nefrologia 2006; 26 Suppl 3:103-8. [PMID: 17469435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023] Open
|
22
|
González-González L, López-Llera M, González-Angulo A, Rubio Linares G, Bierzwinsky Sneider G. Diabetes mellitus and toxemia of pregnancy. Electron microscopic study of renal biopsies. J Reprod Med 1971; 7:133-8. [PMID: 4106495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|